Brief: Wuxi Biologics Secures FDA Pli Approval For Five Facilities, First For Commercial Pfs Line
July 22 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK: WUXI BIOLOGICS SECURES FDA PLI APPROVAL FOR FIVE FACILITIES, FIRST FOR COMMERCIAL PFS LINE Source text: ID:nPremPhDVa Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln